文献速递白血病

克拉屈滨在18至65岁新诊断急性髓系白血病患者中的治疗价值

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.
PubMed 文献 · Blood · 2017-01-03

研究纳入18至65岁新诊断急性髓系白血病或高危骨髓增生异常综合征患者,随机比较标准化疗联合或不联合克拉屈滨的诱导方案。完全缓解率无差异,克拉屈滨组缓解更快但毒性增加、造血恢复延迟;中位随访36个月,总生存和无事件生存无差异,克拉屈滨组复发率降低但缓解期死亡概率增加;亚组分析显示克拉屈滨仅改善中危I组及NPM1野生型/FLT3无内部串联重复亚组的生存。

要点

  • 克拉屈滨联合诱导未改善总体完全缓解率,但缓解更快(第一周期后66% vs 75%)。
  • 中位随访36个月,两组总生存和无事件生存无差异,克拉屈滨组复发率降低但缓解期死亡增加。
  • 克拉屈滨仅改善中危I组及NPM1野生型/FLT3无内部串联重复亚组的生存。

核心结论

  • 克拉屈滨仅改善部分中危急性髓系白血病亚组的生存,总体生存和无事件生存无差异。

研究设计与样本

  • 研究纳入18至65岁新诊断急性髓系白血病或高危骨髓增生异常综合征患者,随机分配至对照组或克拉屈滨诱导治疗组,可评估病例分别为402例和393例。

主要发现

  • 完全缓解率89%两组无差异,但克拉屈滨组缓解更快(第一周期后66% vs 75%)。
  • 中位随访36个月,对照组4年无事件生存35%±3(标准误),克拉屈滨组38%±3,两组无差异。
  • 克拉屈滨组复发率44%±3 vs 对照组35%±3,克拉屈滨组降低;缓解期死亡概率15%±2 vs 22%±3,克拉屈滨组增加。
  • 中危I组4年无事件生存:对照组26%±4 vs 克拉屈滨组40%±5(Cox P=0.002)。
  • NPM1野生型/FLT3无内部串联重复亚组4年无事件生存:对照组18%±5 vs 克拉屈滨组40%±7(Cox P<0.001)。

局限性

  • 克拉屈滨增加了3至4级毒性并延迟造血恢复。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clofarabine has demonstrated antileukemic activity in acute myeloid leukemia (AML) but has yet to be critically evaluated in younger adults in the frontline with standard chemotherapy. We compared 2 induction regimens in newly diagnosed patients ages 18 to 65 with acute myeloid leukemia (AML)/high-risk myelodysplastic syndromes, that is, idarubicine-cytarabine (cycle I) and amsacrine-cytarabine (cycle II) without or with clofarabine (10 mg/m2 on days 1-5 of each of both cycles). Consolidation involved chemotherapy with or without hematopoietic stem cell transplantation. Event-free survival (EFS, primary endpoint) and other clinical endpoints and toxicities were assessed. We randomized 402 and 393 evaluable patients to the control or clofarabine induction treatment arms. Complete remission rates (89%) did not differ but were attained faster with clofarabine (66% vs 75% after cycle I). Clofarabine added grades 3 to 4 toxicities and delayed hematological recovery. At a median follow-up of 36 months, the study reveals no differences in overall survival and EFS between the control (EFS, 35% ± 3 [standard error] at 4 years) and clofarabine treatments (38% ± 3) but a markedly reduced relapse rate (44% ± 3 vs 35% ± 3) in favor of clofarabine and an increased death probability in remission (15% ± 2 vs 22% ± 3). In the subgroup analyses, clofarabine improved overall survival and EFS for European Leukemia Net (ELN) 2010 intermediate I prognostic risk AML (EFS, 26% ± 4 vs 40% ± 5 at 4 years; Cox P = .002) and for the intermediate risk genotype NPM1 wild-type/FLT3 without internal-tandem duplications (EFS, 18% ± 5 vs 40% ± 7; Cox P < .001). Clofarabine improves survival in subsets of intermediate-risk AML only. HOVON-102 study is registered at Netherlands Trial Registry #NTR2187.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Löwenberg B, Pabst T, Maertens J, et al. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood. 2017. PMID: 28049642. doi:10.1182/blood-2016-10-740613

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。